How well can scars of the heart muscle be seen and measured when using a reduced contrast dose for MRI imaging of the heart?
- Conditions
- Imaging and quantification of myocardial scars in patients with acute or chronic myocardial infarction, inflammatory heart disease, or hypertrophic cardiomyopathyCirculatory SystemAcute myocardial infarction, other forms of chronic ischaemic heart disease, hypertrophic cardiomyopathy, myocarditis, unspecified
- Registration Number
- ISRCTN40864982
- Lead Sponsor
- Charité - University Medicine Berlin
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- All
- Target Recruitment
- 280
1. Written consent of the patient prior to commencement of study-specific actions
2. Capable of giving consent and capable of understanding the nature and scope of the clinical trial
3. Aged =18 years
4. Confirmed diagnosis or suspected diagnosis of acute or chronic myocardial infarction, inflammatory heart disease, or hypertrophic cardiomyopathy
5. Clinically indicated cardiac MRI examination with gadolinium-containing contrast agent according to the disease present
1. Absolute contraindication to MRI examination (e.g. presence of metal implants, insulin pumps, pacemakers, ICDs, orbital foreign bodies, non-MRI cochlear implants, cerebral vascular clips)
2. Known allergy to MRI contrast media
3. Pregnant or breastfeeding
4. Have already participated in this study
5. Refusal to participate
6. Not capable of giving consent
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Scar mass measured using a semi-automatic thresholding-based approach (full width at half maximum) at a single timepoint (the time the MRI image was taken)
- Secondary Outcome Measures
Name Time Method Synthetic full-dose recording performance compared to the reference standard measured by the signal-to-noise ratio and contrast-to-noise ratio of the MRI image at the single timepoint